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characterized by a spectrum of neuroendocrine markers. Non-SCCL on the other hand is deprived of these characteristics, or express them in low quantities. The cell surface is of major importance for inter-and intracellular communications via specific receptors and transport mechanisms. The surface membrane is composed of a vast number of glycoproteins (GP) and glycolipids (GL) , but their specific functions are still mainly unknown.
The descriptive analyses of the surface GP using the galactose-oxidase tritiated sodium borohydride technique and 1251 labelling techniques have demonstrated that SCCL expresses a different pattern of surface GP as compared to non-SCCL. The principal patterns of these GP also seem to remain unaltered during prolonged in vitro cultivation and upon growth in defined medium. The surface GL of SCCLs contain a specific monosialoganglioside, fucosyl-GMI, and 2-hydroxy-fatty acids as major gangliosides in high frequency of examined biopsies. In contradistinction to the surface GP, these 'specific' GL seem to be altered during prolonged in vitro cultivation of SCCL cell lines. Much research has been devoted to the biochemistry of lung cancer cells with a view to identifying markers for clinical application and for tracing cell lineage relationships between the major forms of lung cancer. The endocrine status of small cell lung cancer (SCLC) has led to the evaluation of peptide and non-peptide hormones, enzymes and structural proteins as diagnostic markers for the SCLC phenotype. However, it is now generally accepted that many of these substances are associated with all the histological types of bronchogenic carcinoma. Whilst the presence or absence of a given biochemical marker may be of little diagnostic value, certain biomarkers may be useful for monitoring therapy particularly in patients with SCLC where a relationship between tumour burden and levels of NSE, calcitonin and ACTH has been demonstrated. However, there exists no single marker for which elevated levels can be measured in all patients with lung cancer and in many recurrences, markers rise indistinctly or too late to be clinically useful, or not at all. The A restriction fragment length polymorphism (RFLP) has been shown to be associated with the human c-Ha-ras gene. The RFLP has been shown to result from the variation in size of a region of repetitive DNA, approximately lkb 3' of the polyadenylation signal of the gene. Four common alleles have been identified (al to a4) with occasional rare variants and Krontiris et al (1985) Nature 313, 369 suggested that rare alleles predisposed an individual to cancer.
The c-Ha-ras allele frequency has been studied in a group of lung cancer patients and unaffected controls. The patients were divided into two groups (a) individuals with small cell carcinoma (SCCL) (b) those with non-small cell carcinoma (N-SCCL). No significant variation in the frequency of rare alleles was found between the groups of cancer patients and unaffected controls. However a significant difference in the frequency of one allele (a4) was found between individuals with N-SCCL and unaffected controls (P <0.05) and between those with N-SCCL and SCCL (P <0.004) This suggests a degree of genetic predisposition to N-SCCL. Molecular genetic studies on a large panel of human small cell lung cancer (SCLC) lines have revealed a consistent set of abnormalities that could potentially explain part or all of the malignant phenotype of these cells. First, restriction fragment polymorphism analysis (by Dr S. Naylor, Univ. Texas) has demonstrated that the cytogenetic deletion of chromosome region 3p (14-23) represents a true DNA deletion. This suggests SCLC may have similar genetic mechanisms operating, as those in retinoblastoma and Wilm's tumours. Second, frequently we have found amplification or deregulated expression of the myc family of oncogenes (including c-, N-, and L-myc) as well as expression of the p53 proto-oncogene. The structure and expression of L-myc are particularly interesting as alternative processing of L-myc mRNA is seen in both small cell and non-small cell lung cancer groups. This alternative processing generates messages with different combinations of the 2nd and 3rd exon myc family equivalents, a feature not yet described for c-myc or N-myc. In addition, expression of cellular proto-oncogenes of the ras and raf (studies by Dr U. Rapp, NCI) families in these same cells set the stage for oncogene cooperation. Finally, it appears that both SCLC and non-SCLC lines can replicate in serum-and hormonefree medium for prolonged periods of time indicating their ability either to produce autocrine growth factors (such as gastrin releasing peptide) or Despite having led the world in the epidemiology of smoking and still having the highest death rate from lung cancer in the world, the UK has a far from satisfactory record in the implementation of effective anti-smoking measures. It was one of the first countries to implement such measures, but still has no overall government policy on smoking and the health department policy is not comprehensive and falls far short of standards set by WHO, UICC, the Royal College of Physicians and other agencies. Nevertheless, the present decline in consumption is among the fastest in the world. An ideal smoking control policy includes action in the areas of health education, public information, tobacco promotion, smoking in public places, taxation and the reduction of emission levels of tar, carbon monoxide and nicotine. Outstanding in recent years has been the UK's performance on the increase of the real price of cigarettes by means of regular tax rises. Performance has been disappointing, however, in restricting advertising and other forms of promotion in public places, both energetically resisted by the tobacco industry. Health education has been low in status, priority and expenditure but public information work through the news media has been comparatively successful. Combination chemotherapy has improved median survival in small cell lung cancer (SCLC) but the proportion of patients surviving beyond 2 years is less than 10%. Attempts to improve results by alternating drug regimens have not been successful, but active new agents such as carboplatin, ifosfamide and VM26 have yet to be incorporated into multiagent regimens. The optimum duration of combination chemotherapy has not been determined. Recent Retroviruses are well known aetiological agents of lymphoma in fish, birds and mammals. Since 1980, retroviruses have been identified in association with lymphoma in man. Human T-cell leukaemia virus type I (HTLV-I) is the principal cause of adult T-cell leukaemialymphoma (ATLL), a malignancy of mature T4 lymphocytes prevalent in Japan and the Caribbean. Lymphomas are also the second commonest tumour in AIDS, a syndrome caused by another kind of retrovirus, the human immunodeficiency virus type (HIV-1). In ATLL, the retrovirus directly induces T-cell transformation leading to eventual malignancy, whereas in AIDS, the lymphomas are generally EBV-positive B-cell neoplasms probably arising as a result of immunosuppression induced by HIV-1. Current ideas on the molecular mechanisms of cell transformation and immunosuppression by human retroviruses will be reviewed. Lymphomas offer a wealth of differentiation antigens for exploitation either as tumour markers or as targets for therapeutic antibody. Preeminent antigens as regards specificity and characterisation are the idiotypes of surface Ig and the T-cell receptor. Therapeutic antibody can damage the tumour by delivering to it an exogenous toxic agent, or by recruiting the host's own cytotoxic agents such as complement and various cellular effectors. The latter strategy is the one that we have studied the more intensively.
We are using chimeric univalent derivatives of monoclonal antiidiotype antibodies to treat human B-cell lymphoma. The derivatives recruit host effectors efficiently, avoid rapid antigenic modulation, and have a good metabolic survival. Our current protocol provides them for intramuscular injection, which is vastly more convenient than intravenous infusion. Results, problems and future trends will be discussed. In this study we have examined biopsies from 15 untreated patients with SCCL using 35-S-labelled RNA probes against N-myc. Deparaffinized sections were used after proteinase K and acetic anhydride-glycine treatment with a 1.7Kb EcoRI-Bgl 11 genomic fragment of the third exon of the human N-myc. A primary lung-adenocarcinoma biopsy was used as positive control, while this tumour previously has been demonstrated to contain N-myc amplification using Southern blots. To evaluate the results of the SCCL biopsies the number of grains was calculated. Six of 7 patients with complete responses and a median survival time of 22 months (range 9-64 months) were negative for N-myc expression. The 6 patients with N-myc positive SCCL biopsies had, together with 2 negative patients, only partial-or no responses; with a median survival of 13 months (range 6-16 months).
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Intermittent chemo/radiotherapy in small cell lung cancer: A novel approach to combined modality therapy The role of thoracic radiotherapy (TRT) in small cell cancer is controversial even in limited disease (LD). Concurrent chemotherapy (CT) and TRT may confer benefit, but at the expense of substantial local toxicity. In this study TRT is used as a localized cytotoxic agent given intermittently the day following i.v. CT.
Forty-eight patients are currently on study. Eleven patients received VACR (dl: vincristine 1 mgm-2, adriamycin 40 mgm -2, cyclophosphamide 1000 mgm-2i.v.; d2: TRT 400 cGY-q2ld x 6). In order to assess the potential lack of cross-resistance with adriamycin (ADR) of 5 novel anthracycline analogues, studies have been performed with 2 human non-small cell lung cancer cell lines (A549 and SK-MES-1) of differing inherent sensitivity to ADR. The 5 compounds are idarubicin (IDA), 4'-deoxy-4'-iododoxorubicin (JODO) both supplied by Farmitalia; a 9-methyl derivative (Ro3l/1215) supplied by Roche; a cyanomorpholino derivative (MRA-CN) supplied by SRI International, and a 7-hydroxyanthrapyrazole (CI941) supplied by Warner Lambert. Cells of the 2 cell lines were seeded onto microtitre plates and, after 96h, were exposed to drug for a further 72 h (with drug replacement at 24 and 48 h) followed by a recovery period of 120 h. Viability at the end of the assay was assessed as tritiated leucine incorporation. Results made little difference to the ADM sensitivity of the parent line but considerably sensitised the resistant line, thereby reducing the RF to around 3. The magnitude of the effect was reduced with reducing dose of CYA, but some sensitisation was still observed at 0.5 jigml-1. Similarly the RF for VCR could be reduced from 1,000 to 10 by 5 jg ml -1 of CYA. This resulted from a 300-fold sensitisation of the resistant line compared with a 3-fold sensitisation of the parent line. Cyclosporin C and cyclosporin G, analogues possessing immunosuppressive properties, each showed similar activity to CYA at a dose of 5 jig ml-1. The biologically inert analogue cyclosporin H, however, had little or no activity at 10 jig ml -1. Qualitatively similar results were obtained using the drug resistant variant of the EMT6 cell line.
These studies suggest that cyclosporins, at clinically achievable doses, may have a role as specific sensitisers of chemotherapy-resistant tumours. The acute in vitro responses to radiation of a panel of human lung carcinoma lines, representing 3 of the common histological types, were determined using a soft agar clonogenic assay. (A squamous carcinoma failed to clone using this technique). The survival data were analysed according to the multitarget and linear quadratic models, and the surviving fraction at 2 Gy (SF2). The mean Do of the classical small cell carcinomas (1.26 + 0.11) was significantly lower than that of the other cell types (1.63 +0.09, P < 0.01). Significant differences in a, representing the initial slope of the cell survival curve, were also found between the lines: the mean oc of the lines with a large cell component (0. 64, 298, 1983 47, 361, 1983) . Gamma interferons differ from the x-molecule, notably possessing greater cytotoxic and immunomodulatory activity. Immuneron (r-IFN-y) has been shown to inhibit the growth of small cell lines in vitro (Twentyman, P.R. et al., Br. J. Cancer, 52, 21, 1985) . This agent was therefore assessed under optimal conditions in previously untreated patients. A dose of 1 mgm-2 day-1 for 5 days continuously was followed by a maintenance dose of 0.5 mgm 2 thrice weekly, being given i.v. over 30 min. The trial was stopped after 12 of the 14 projected patients had been treated, because of poor responses. Four patients are considered non-evaluable for response; one was withdrawn because of hypotension, one developed spinal cord compression, and two died from intercurrent illness not thought to be Immuneron related. Of the remaining 8 patients 4 had stable disease for 1 month, and 4 had progressive disease within 3 weeks on therapy. Toxicity consisted mainly of pyrexia (11/12) and malaise (10/12). The lowest total WBC was 2.0, and transient rise in SGPT at the end of week 1 was seen in 9/12 patients. Paired serum for E. coli and r-IFN-y antibodies were taken and results will be presented. Ten We have previously shown that 4-hydroxyandrostenedione (4-OHA), a potent aromatase inhibitor has significant antitumour activity when administered parenterally to postmenopausal women with breast cancer. This is the first report of the use of 4-OHA administered orally.
Thirty-one female patients, mean age 65.7yrs (range 40-82 yrs) with locally advanced or inoperable breast cancer were treated with 4-OHA given orally at a dose of 500mg daily. All were postmenopausal. Seventeen (54%) had been given previous endocrine therapy with 1 agent, 6 (19%) had received 2 agents and 3 (10%) had received 3 agents with an overall response rate of 60%. Response to 4-OHA was as follows. Eight (26%) had a partial response (PR) with a median duration > 10 months; 6 remain in remission. Four (13%) patients had stable disease (SD), 11 (36%) had progressive disease (PD) and 8 (25%) were not evaluable. Ten patients had ER positive tumours and 5 (50%) responded (PR+SD). One of 9 patients with ER negative tumours responded and 6 (50%) of 12 patients with ER unknown tumours responded (PR+ SD). In 16 of the 31 patients serial plasma oestradiols were measured and were lowered to 53+8% of baseline levels within 7 days of commencing 4-OHA. Thirty patients were evaluable for toxicity. Twenty-seven (90%) experienced no side effects; a patient had an erythematous skin rash and 1 patient had facial swelling. In 1 patient treatment was discontinued due to leucopaenia (WBC=2.5).
Oral 4-OHA is a new treatment for post menopausal women with breast cancer which has few side effects. We are evaluating the use of high dose BCNU (800mg-1 gm-2) with autologous bone marrow grafting as the first post-surgical treatment of patients with astrocytoma grade IV. It is followed by full dose radiotherapy. Detailed pharmacokinetic studies using reverse phrase HPLC indicate that peak plasma concentrations range from 8.5-15.9pgml-1 in the 5 patients studied. Rapid biphasic elimination occurs in the first 12 h, with concentrations at that time ranging from 0.03-0.056 jug ml-1 with some evidence of a third phase. Returning the bone marrow graft at 24-30h allowed successful reconstitution.
Seventeen patients have been treated on this programme. Median follow up 1 year (range 3-27 months). Nine patients remain alive, with 2 year actuarial probability of survival of 55%, comparing favourably with historical experience. Leucopenia and thrombocytopaenia were of short duration, but there were 3 cases of pneumonitis, 2 of which were fatal, and 1 fatal hepatic toxicity. This approach to high grade glioma deserves further evaluation in a controlled trial. Is Recent advances in chemotherapy (CT) have led to the prospect of cure for the majority of men with advanced testicular cancer. We have studied the long-term physical side-effects of such treatments. Thirty-six patients (pts) who had been treated with CT for testicular cancer in the period [1979] [1980] [1981] [1982] [1983] and who remained disease-free were asked to take part in the study; 24 agreed to do so. Mean age of study pts was 33 (range 20-51), median time since start of CT was 33 months (6-63). All pts had received cis-platinum (CPt), bleomycin (B) and vinblastine (V). Mean doses given (range) were CPt 647mg (300-1190), B 320mg (135-675), V 75mg (40-160). Four pts had also received etoposide and 3 pts actinomycin-D. Median number of courses of CT given was 3.5.
Renalfunction: Prior to CT all pts had normal serum urea and creatinine. After CT 2 had raised urea and 3 raised creatinine. Creatinine after CT showed a strong correlation with total dose of CPt. There was no correlation with age or time since treatment. Endocrine junction: All pts had normal serum testosterone and free-T4. 11/21 (52%) had raised TSH, 16/24 (67%) had raised LH and 18/24 (75%) had raised FSH. Endocrine dysfunction was more severe in older patients. Audiometry: Prior to CT 5 pts had audiometric testing. Four were normal, 1 showed unilateral hearing loss. The majority of pts had objective high-tone hearing loss with 50% having <20db mean hearing loss for both ears at 6-8 khz. Seven pts (29%) had subjective hearing loss. Extent of high-tone hearing loss was strongly correlated with total dose of CPt but not with age. Semenalysis: 4pts had no semenalysis. All pts not azoospermic on first testing were asked to have repeat semenalysis; 13 agreed. Thus 33 semenalyses were done in 20pts. Total dose of CPt and V were strongly correlated with reduced sperm counts (SC), reduced motility and reduced % of motile sperm. There were no correlations with age. Pulmonary Function: Peak flow rate and CO transfer factor were below predicted for height, age and ethnic origin in more patients than would be expected by chance although only in one pt was CO transfer factor reduced below 2 standard deviations of predicted and there was no correlation with dose of bleomycin. Inspiratory capacity, vital capacity and effective alveolar volume were within the predicted range in all pts but each showed significant inverse correlations with total dose of bleomycin.
CT for testicular cancer causes long-term disturbance of renal, endocrine, pulmonary, audiometric, and reproductive function which is largely dose-related. Except for hearing loss this disturbance is asymptomatic but further follow-up is required to determine whether these abnormalities have any future significance. Although DNA mediated induction of transformed foci in NIH3T3 monolayers has been widely used as an assay for activated oncogenes in human tumours, its usefulness has been limited by a high and variable incidence of background spontaneous foci. We set out to correct this by examining the influence of (a) serum concentration, (b) feeding interval, (c) medium composition and (d) plastic surface, on (i) the incidence of spontaneous foci, and (ii) the incidence of true foci induced by transforming sequences, using plasmid pSV2neoEJ containing activated Ha-ras as a positive control. Using 'high background' NIH3T3 cells (which had been serially-passaged for 6 months) in standard culture conditions -5% calf serum (CS), with a 3 day feeding interval using DME medium on 90mm Nunc dishes -we observed a spontaneous focus incidence of 20/dish and a true focus incidence of 21/dish. (a) Simply adjusting the serum concentration was not successful since concentrations below 5% failed to support a viable monolayer while higher concentrations increased the spontaneous focus rate. (b) Keeping the serum concentration at 5% but reducing the feeding interval to 1 day, however, dramatically reduced the spontaneous focus incidence (to 0/10 dishes) giving a reproducibly uniform monolayer. Furthermore the true rate was improved to 55/dish. (c), (d) Use of a 'richer' medium (DMEM: F12/1:1) and Falcon dishes both gave further improvements in the true focus rate (up to 154/dish) with no deterioration in the background.
Our results demonstrate a dramatic improvement in the 'signal to noise' ratio of the focus assay by simple adjustment of culture conditions without recourse to recloning. While the majority showed a range of intensities (from 10-100 grains/cell after 7 days exposure), 20% of cells were intensely labelled (>200 grains/cell) whereas 20% were indistinguishable from background (<3 grains/cell). In a preliminary study of medullary carcinoma of the thyroid, using both frozen and paraffin sections. c-myc was not detectable above the background, non specific signal (<3 grains/cell) in 4 out of 5 tumours, and in normal thyroid and other control tissues. One case, however, was clearly positive. In this tumour, while a weak signal (10-20 grains/cell) was observed over the majority of the cells, one nodule (representing -10% of the total tumour area observed in the section) was intensly positive (>200 grains/cell). These examples of heterogeneity of oncogene expression clearly demonstrate the additional information which can be obtained by in situ compared with homogenate-based hybridisation. Riggs, Science, 210, 604 (1980) ). Quantitation of this product involving the degradation of DNA to purine and pyrimidine bases has been inaccurate because deamination of cytosine and 5-methylcytosine occurs during the hydrolysis procedure (J.P. Ford et al., J. Biol. Chem., 255, 7544 (1980) ). We have therefore undertaken a systematic study of the hydrolysis of DNA by hydrofluoric acid (HF). Separation of the bases was achieved using a Nucleosil 5 SB column eluted with 10mm sodium acetate pH 4.0 containing 30% methanol, and quantitation at 280 nm was by automated peak area integration. Deoxycytidine and 5-methyldeoxycytosine were shown not to undergo detectable levels of deamination during prolonged periods (up to 24 h) at 80"C in 48% HF. Kinetic studies showed that the release of purine and pyrimidine bases was complete by 4 h under these conditions. Analysis of the 5-MeC content of DNA from Herring testis and Calf thymus gave 5-MeC levels of 9.62% and 6.67% respectively i.e. very close to the literature values of 10.8% and 6.6% (G.D. Fasma (ed.), Handbook of Biochemistry and Molecular Biology, 3rd Edn. p. 241 (1976) Transfection of cells with cloned genes or total genomic DNA offers opportunities for studying the regulatory disturbances responsible for aspects of neoplastic behaviour.
We have used this method to examine whether incorporation of the cloned 6.6kb fragment of the mutated c-Ha-ras human oncogene into the genome of 3T3 fibroblasts can confer metastatic capability on these cells. 3T3 cells cotransfected with the mutated ras gene and the neomycin resistance plasmid psv2-neo were selected by culture in neomycin. On subcutaneous inoculation into MFI nude mice these cells proved to be tumorigenic with short latent periods (-14 Studies aimed at determining the histogenesis of the ReedSternberg cell, the putative neoplastic cell of Hodgkin's lymphoma, have been hampered in the past by difficulties encountered in preparing pure suspensions of such cells. Recently however, a number of cell lines derived from Hodgkin involved tissue have become available and whilst it is not certain that these genuinely represent the ReedSternberg cell population, they do share certain characteristics in common with their in vivo counterparts. We have undertaken to analyse by SDS-polyacrylamide gel electrophoresis (PAGE), Western blotting and lectin probing, the cellular glycoprotein profiles of four Hodgkin cell lines (L428 and L59 1, Diehl et al., Cancer Treatment Rep., 66, 615, 1982; Ho and Co; Jones et al., Haematol. Oncol., 3, 133, 1985) and compare these with profiles obtained for cell lines of established lymphoid, myeloid or monocytoid origin. Six 1251 labelled lectins representing the most common carbohydrate specificities were used to probe nitrocellulose membranes of SDS-PAGE separated detergent solubilised cellular glycoproteins for each cell line studied. Lectins binding to specific bands were visualised by autoradiography and molecular weights (Mr) calculated by reference to a standard calibration curve. The complex glycoprotein profiles obtained for the Hodgkin cell lines studied suggest these cells to be of lymphoid origin, an observation in agreement with both immunophenotypic and immunoglobulin/T cell receptor rearrangement studies. Work is now in progress to raise monoclonal antibodies against specific glycoprotein bands of interest for use as immunocytochemical probes on tissue section. Preparation of monoclonoclonal anti-idiotype reagents for monitoring and therapy of B cell neoplasms is dependent on a supply of idiotypic Ig as immunogen. This is not readily available from tumours which do not secrete or display high levels of Ig. Such patients frequently have low levels of urinary monoclonal light chain of neoplastic origin. The object of this study was to investigate whether monoclonal antibody raised against isolated light chain idiotype also recognised determinants in intact (heavy + light chain) idiotypic Ig, allowing urinary light chain to serve as alternative immunogen. A hybridoma was selected secreting antibody which recognised idiotypic A of patient L.P., but not normal A chains by a preliminary screen, and which also reacted with idiotypic IgMA on the patient's tumour cells. An immunotoxin (IT) composed of monoclonal anti-idiotype (Id) coupled via disulfide linkage to the plant ribosomeinactivating protein saporin, has been investigated in the treatment of guinea pig L2C leukaemia. In vitro this conjugate remained toxic to L2C cells, as measured by the incorporation of [3H] leucine into protein, at below 10-10M and was respectively > 10,000 and 900 times more potent than free saporin and saporin coupled to an antibody of irrelevant specificity. In therapy a single s.c. injection of reactive IT given 24h after an i.p. inoculum of 105 L2C, increased the mean survival of animals from 15 days to 30 days. Under the same conditions control reagents, including free saporin, anti-Id alone or saporin coupled to a nonreactive antibody, did not prolong animal survival. All L2C cells emerging after IT therapy showed altered immunoglobulin (Ig) expression which rendered them non-reactive with the IT. Predominantly L2C cells had lost p heavy chain production leaving them negative for intracellular, surface and secreted IgM, but still positive for idiotypic light chain production. In addition a minor group of L2C variants did express normal levels of IgM but with an altered or mutated Id which rendered them non-reactive with the IT.
Our previous immunotherapy investigations using monoclonal anti-Id alone have not revealed these Ig variants. We suggest that it is the increased selective force exerted by the highly potent IT which allowed non-reactive populations to emerge. Such cells, particularly those of an Ig negative phenotype, could prove a major obstacle to the application of IT therapy in humans. Idiotypic determinants on the surface immunoglobulin of B cell tumours are tumour-associated antigens and therefore present a target for anti-idiotypic attack. Immunization of mice with idiotypic IgM from the syngeneic BCL1 lymphoma has been used to generate anti-idiotypic responses and to follow the effect on tumour development. Such immunization protects specifically against challenge with some mice surviving >6 months. Spleens from long-term survivors with no macroscopically visible tumour, when examined with anti-idiotypic antibody, showed a range of apparently dormant tumour occupying 2-50% of the spleen. On the passage of these spleen cells into naive mice, BCL1 tumour developed and killed the recipients in times indistinguishable from routine tumour passage. Analysis of possible mechanisms of suppression in immunized mice identified low levels of cytotoxic anti-idiotypic antibody in serum and splenic T cells which proliferated specifically in response to idiotypic IgM Patients in apparent complete remissiont (CR) from multiple myeloma following treatment with high dose melphalan were monitored for residual disease using a sensitive anti-idiotype (Id) enzyme-linked immunosorbent assay (ELISA) capable of detecting low levels of tumour-derived idiotypic Ig. High titre anti-Id anti-serum was prepared for each patient in rabbits, using idiotypic myeloma Ig isolated from pretreatment sera as a source of immunogen. Reactivity towards common immunoglobulin (Ig) determinants was removed by extensive absorption against pooled human IgG and/or IgA as appropriate, and then antibodies were affinity purified by elution from a column of the patients' purified idiotypic Ig. In the ELISA these purified anti-Id antibodies were used as a coating layer to capture the patients idiotypic Ig from test sera, before detecting with an enzyme-labelled antihuman Ig antibody. The specificity of each anti-Id reagent was fully established against pooled human serum and irrelevant immunoglobulins.
Ten patients are under investigation in the current study. All achieved CR as judged by conventional criteria, including the absence of a monoclonal band from electrophoretic strips of the patients' sera. Despite these indications the sensitive ELISA system presented has shown that in all 6 patients monitored so far, idiotypic myeloma protein remained in the circulation throughout the post-treatment period at levels of <l1,000 ug ml-. Three of the 6 patients have since relapsed clinically. We suggest that the monitoring system described could be useful in evaluating CR in the research context. ( A study was made of 81 patients with primary gastrointestinal lymphoma. Forty-four per cent of tumour occurred in the stomach or duodenum; 44% in the small bowel or mesentery; 5% in the colon or rectum; 2% in the ileocaecal region. In the remainder it was not possible to determine the site of origin. The Rappaport histological classification was used. The commonest histological subtype was diffuse histiocytic (48%). This group had a poor prognosis with a median survival of 14 months; in contrast, the lymphocytic lymphomas fared better, irrespective of nodularity or differentiation. The patients were staged according to the system proposed by Blackledge. Stage I had the best prognosis (5-year survival 73%); in contrast, there were no stage 4 5-year survivors. Eighty-four per cent of patients had some form of surgical resection; prognosis was better in those where the resection was complete. The majority of patients received in addition radiotherapy or chemotherapy; survival in the surgery/radiotherapy group was better than in the surgery/chemotherapy group. Overall 5-year survival was 43%. Oesophageal carcinoma is such a rare tumour (5 per 100,000) that population based studies on changes in the incidence by both sub-site and histology have not hitherto been possible. In a study of 6,398 cases occurring in the West Midlands Region over the 25 year period the numbers were sufficient to enable marked differences to be observed within classifications by both parameters.
The categorisation by site was into upper, middle and lower thirds. Tumours of doubtful origin were reviewed and those arising in either the hypopharynx or cardia were rigorously excluded. It was not possible to specify a subsite within oesophagus for -12% of the cases, but as this proportion has remained relatively constant throughout the period it is unlikely to have introduced any bias. The histological breakdown was into squamous, adenocarcinoma, anaplastic and 'no histological confirmation' (30%). To compensate for changes in the age structure of the population, age-standardised incidence rates were used.
Results indicate a steady increase in incidence of the middle and lower thirds for both sexes. Tumours of the upper third and of unspecified site remained relatively stable, indicating that this increase is a real one and not the result of changes in classification. The increase in the middle third occurred in squamous and in adenocarcinomas and in both sexes. In anaplastic carcinomas the increase was only in females. In the lower third there was an increase in squamous cell carcinoma in women but not in men. For adenocarcinomas the rates increased in both sexes and was highly significant in men. Anaplastic carcinomas showed little change. Neoplastic tissue was obtained at operation from 10 renal cell carcinomas, from the adjacent normal kidney in 6 cases and from I other normal kidney. The biopsies were snap frozen in liquid nitrogen and sections were subsequently stained with monoclonal antibodies against major histocompatibility complex antigens, Class I and II, and several types of mononuclear cell, by the indirect immunoperoxidase method. The degree of staining was graded from heavy 4, through moderate 3, few 2, occasional 1, to nil 0. MHC Ag were consistently expressed, grad 3-4, by the glomerular basement membranes and proximal convoluted tubules of normal kidney, but were absent in 8 of 10 carcinomas. There was a grade 3-4 mononuclear cell infiltration in the stroma of normal kidney and between the carcinoma cells which was composed principally of macrophages. However, in the two carcinomas expressing MHC Ag there was a grade 2-3 infiltration with T lymphocytes. Peripheral blood lymphocytes (PBL) of 4 patients with malignant effusions were stimulated for 6 days with purified autologous tumour cells, before isolation of the lymphoblasts and cloning by limiting dilution in interleukin-2 (IL2). Fortyfive clones were analyzed for cytotoxicity (CTX) against autologous, allogeneic and cell-line targets of known status with respect to expression of major histocompatibility complex (MHC) antigens, estimated by reaction with the W6/32 (anti HLA, -A, -B, -C monomorphic) and TDR3 1.1 (anti HLA-DR) monoclonal antibodies (McAb) . Twenty-one of the 45 clones were cytotoxic, 7 for the autologous target only, the remainder exhibiting various degrees of activity against allogeneic and cell-line targets as well. All Evidence suggests that drug resistance in tumours frequently arises as a consequence of spontaneous somatic mutation (Goldie & Coldman, Cancer Treatment Rep., 63, 1727 , 1979 . The measurement of mutation frequency could therefore be useful in cancer management as an index of the tumour's potential to become resistant to therapy, Because current techniques for cloning human solid tumour cells manifest low cloning efficiencies, they are unsuitable for the detection of rare spontaneous mutants. An alternative approach to this problem is the use of the thymidine analogue 5'-bromodeoxyuridine (BrUdR). Cells that continue to proliferate, i.e. incorporate BrUdR, in the presence of a selective agent are immunofluorescently stained using our anti-BrUdR monoclonal antibody. This small proportion of resistant cells is quantitated flow cytometrically. 6-Thioguanine (6TG) resistance, usually attributed to a lack of the enzyme hypoxanthine phosphoribosyltransferase (HPRT), was measured in two cell lines, CCRF-CEM (human T-cell leukaemia) and L1210 (mouse T-cell line). The frequency of BrUdR positive cells, after treatment with 6TG, was found to be 3.0 x 10 and 3.3 x 10 respectively. The biological significance of the BrUdR positive cells was validated by pre-treatment of cell samples with HAT medium, thus removing the HPRT population, and by comparison with results from cloning assays. The method has been successfully used with tumour cell lines and its application to human tumours is being assessed.
